These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1246 related articles for article (PubMed ID: 25965710)

  • 1. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
    Bentley-Lewis R; Aguilar D; Riddle MC; Claggett B; Diaz R; Dickstein K; Gerstein HC; Johnston P; Køber LV; Lawson F; Lewis EF; Maggioni AP; McMurray JJ; Ping L; Probstfield JL; Solomon SD; Tardif JC; Wu Y; Pfeffer MA;
    Am Heart J; 2015 May; 169(5):631-638.e7. PubMed ID: 25965710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
    Muskiet MHA; Tonneijck L; Huang Y; Liu M; Saremi A; Heerspink HJL; van Raalte DH
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):859-869. PubMed ID: 30292589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
    Pfeffer MA; Claggett B; Diaz R; Dickstein K; Gerstein HC; Køber LV; Lawson FC; Ping L; Wei X; Lewis EF; Maggioni AP; McMurray JJ; Probstfield JL; Riddle MC; Solomon SD; Tardif JC;
    N Engl J Med; 2015 Dec; 373(23):2247-57. PubMed ID: 26630143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.
    Seferovic JP; Bentley-Lewis R; Claggett B; Diaz R; Gerstein HC; Køber LV; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Pfeffer MA
    J Diabetes Res; 2018; 2018():1631263. PubMed ID: 30648112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.
    O'Donoghue ML; Glaser R; Aylward PE; Cavender MA; Crisp A; Fox KA; Laws I; Lopez-Sendon JL; Steg PG; Theroux P; Sabatine MS; Morrow DA
    Am Heart J; 2015 May; 169(5):622-630.e6. PubMed ID: 25965709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
    JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
    O'Donoghue ML; Glaser R; Cavender MA; Aylward PE; Bonaca MP; Budaj A; Davies RY; Dellborg M; Fox KA; Gutierrez JA; Hamm C; Kiss RG; Kovar F; Kuder JF; Im KA; Lepore JJ; Lopez-Sendon JL; Ophuis TO; Parkhomenko A; Shannon JB; Spinar J; Tanguay JF; Ruda M; Steg PG; Theroux P; Wiviott SD; Laws I; Sabatine MS; Morrow DA;
    JAMA; 2016 Apr; 315(15):1591-9. PubMed ID: 27043082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
    JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Price DL; Chen R; Udell J; Raz I
    Am Heart J; 2011 Nov; 162(5):818-825.e6. PubMed ID: 22093196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
    O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
    JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
    Marso SP; Poulter NR; Nissen SE; Nauck MA; Zinman B; Daniels GH; Pocock S; Steinberg WM; Bergenstal RM; Mann JF; Ravn LS; Frandsen KB; Moses AC; Buse JB
    Am Heart J; 2013 Nov; 166(5):823-30.e5. PubMed ID: 24176437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
    Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
    Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
    Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.
    Wijkman MO; Claggett B; Diaz R; Gerstein HC; Køber L; Lewis E; Maggioni AP; Wolsk E; Aguilar D; Bentley-Lewis R; McMurray JJ; Probstfield J; Riddle M; Tardif JC; Solomon SD; Pfeffer MA
    Cardiovasc Diabetol; 2020 Oct; 19(1):175. PubMed ID: 33046070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
    Lincoff AM; Tardif JC; Neal B; Nicholls SJ; Rydén L; Schwartz GG; Malmberg K; Buse JB; Henry RR; Wedel H; Weichert A; Cannata R; Grobbee DE
    Am Heart J; 2013 Sep; 166(3):429-34. PubMed ID: 24016490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
    Tardif JC; McMurray JJ; Klug E; Small R; Schumi J; Choi J; Cooper J; Scott R; Lewis EF; L'Allier PL; Pfeffer MA;
    Lancet; 2008 May; 371(9626):1761-8. PubMed ID: 18502300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
    Shimada YJ; Cannon CP; Liu Y; Wilson C; Kupfer S; Menon V; Cushman WC; Mehta CR; Bakris GL; Zannad F; White WB;
    Am Heart J; 2016 May; 175():18-27. PubMed ID: 27179720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Ballantyne CM; Barter PJ; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Shah PK; Tardif JC; Chaitman BR; Duttlinger-Maddux R; Mathieson J;
    Am Heart J; 2009 Dec; 158(6):896-901.e3. PubMed ID: 19958854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.